• news.cision.com/
  • Qlife Holding AB/
  • Qlife has prepared a balance sheet for liquidation purposes and the board of directors will convene an extraordinary general meeting (for liquidation purposes)
Svenska

Qlife has prepared a balance sheet for liquidation purposes and the board of directors will convene an extraordinary general meeting (for liquidation purposes)

Report this content

The board of directors of Qlife Holding AB ("Qlife" or the "Company"), has, in accordance with Chapter 25, Section 13 of the Swedish Companies Act, prepared a balance sheet for liquidation purposes, which has been reviewed by the Company’s auditor. The balance sheet shows that the Company’s equity corresponds to less than half of the registered share capital

As communicated in the Company’s year-end report for the financial year 2023, the board of directors of Qlife has, in accordance with Chapter 25, Section 13 of the Swedish Companies Act, prepared a balance sheet for liquidation purposes, which has been reviewed by the Company’s auditor. The balance sheet shows that the Company’s equity corresponds to less than half of the registered share capital. The board of directors will therefore convene an extraordinary general meeting, and the first meeting for liquidation purposes (the “EGM”). The EGM shall examine whether the Company should continue to operate or enter into liquidation. The notice to the EGM will be published shortly.

The board of directors is of the opinion that it is in the best interests of the shareholders and the Company that the Company should continue to operate and will therefore propose to the EGM to resolve on continued operation. The board of directors will also propose to the EGM to resolve on a reduction of the Company’s share capital to cover loss.

This information was submitted for publication, through the agency of the contact person set out above, on 2024-03-21 15:48 CET.

For more information, please contact: 

Thomas Warthoe
Chief Executive Officer (CEO)
Phone: +45 21 63 35 34
E-mail: tw@egoo.health

Qlife is a Swedish company based in Helsingborg, which develops and markets an innovative medical technology platform, Egoo.Health (”Egoo”), with the goal of giving people access to clinical biomarker data when testing at home. The company is listed on the Nasdaq First North Growth Market (ticker: QLIFE). G&W Fondkommission is the Company’s Certified Adviser. For additional information, please visit www.qlifeholding.com.

Prenumerera